Healthcare -
Biotechnology - NASDAQ - US
$ 5.78
-4.46 %
$ 559 M
Market Cap
-12.3
P/E
INCOME STATEMENT
EFFICIENCY
Earnings Waterfall
Trevi Therapeutics, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 51.5 M |
| Operating Income | -51.5 M |
| Other Expenses | -3.61 M |
| Net Income | -47.9 M |
Income Statement
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | |
|---|---|---|---|---|---|---|---|---|---|
| REVENUE | |||||||||
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GROSS PROFIT | |||||||||
| Cost Of Revenue | 0 | 0.1 | 43 K | 50 K | 47 K | 39 K | 23 K | 0 | 4 K |
| Gross Profit | 0 | (0.1) | 43 K | 50 K | 47 K | 39 K | 23 K | 0 | 4 K |
| OPERATING INCOME | |||||||||
| Operating Expenses | 51.5 | 33.9 | 29.9 | 32.5 | 32.5 | 26.6 | 18.4 | 8.2 | 8.6 |
| Selling, General and Administrative Expenses | 12.1 | 10.2 | 10.1 | 9.5 | 10.2 | 7.3 | 4.3 | 2.1 | 1.7 |
| Research and Development Expenses | 39.4 | 23.7 | 19.8 | 23.0 | 22.3 | 19.3 | 14.1 | 6.1 | 6.9 |
| Operating Income | (51.5) | (33.9) | (29.9) | (32.5) | (32.5) | (26.6) | (18.4) | (8.2) | (8.6) |
| PRE-TAX INCOME | |||||||||
| Interest Income Expense | 4 K | 0.4 | 0.8 | 1.2 | 0.5 | 0 | 0.2 | 3.3 | 0 |
| Total Other Income | 3.6 | 4.8 | 0.7 | (1.5) | (0.3) | 0.6 | (2.3) | (4.6) | (2.5) |
| Pre-Tax Income | (47.9) | (29.1) | (29.2) | (34.0) | (32.8) | (26.1) | (20.7) | (12.9) | (11.1) |
| NET INCOME | |||||||||
| Tax Provision | 30 K | 32 K | 36 K | 21 K | 18 K | 18 K | (0.1) | 26 K | 8 K |
| Net Income | (47.9) | (29.1) | (29.2) | (33.9) | (32.8) | (26.1) | (20.5) | (12.9) | (11.1) |
| EPS | 0.47 | 0.29 | 0.45 | 1.49 | 1.81 | 2.22 | 2.29 | 1.43 | 0.69 |